Icatibant Teva B.V (Icatibant Acetate)

Icatibant acetate is a competitive antagonist of the bradykinin B2 receptor. By blocking this receptor, it prevents bradykinin‑mediated vasodilation and increased vascular permeability, which are the primary drivers of swelling in hereditary angioedema.

The prescribed dose of Icatibant is determined by the treating physician based on the patient’s clinical condition and regulatory guidelines. Dosage instructions are provided on the prescription label and should be followed exactly.

Safety of Icatibant in pregnancy and lactation has not been established. Healthcare providers should evaluate the potential benefits against possible risks before prescribing it to pregnant or nursing individuals.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Icatibant is a bradykinin B2 receptor antagonist, whereas other options such as C1‑esterase inhibitor concentrates replace a deficient protein. Icatibant provides rapid symptom relief via subcutaneous injection, while C1‑esterase inhibitors are administered intravenously or subcutaneously and work by restoring the regulatory pathway.

Icatibant solution should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial to maintain stability.

Icatibant is supplied as a solution for subcutaneous injection. The patient or a qualified caregiver injects the prescribed volume into the subcutaneous tissue, typically in the abdomen or thigh, following the instructions provided by the healthcare professional.

Serious risks include hypersensitivity reactions such as anaphylaxis, severe hypotension, and paradoxical worsening of angioedema. Patients should be monitored for signs of allergic reaction and instructed to seek immediate medical attention if severe symptoms develop.

Icatibant is contraindicated in individuals with known hypersensitivity to icatibant acetate or any of the formulation excipients. Patients with uncontrolled severe cardiovascular disease should also avoid use until evaluated by a physician.